DK3023100T3 - Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer - Google Patents
Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer Download PDFInfo
- Publication number
- DK3023100T3 DK3023100T3 DK14826652.1T DK14826652T DK3023100T3 DK 3023100 T3 DK3023100 T3 DK 3023100T3 DK 14826652 T DK14826652 T DK 14826652T DK 3023100 T3 DK3023100 T3 DK 3023100T3
- Authority
- DK
- Denmark
- Prior art keywords
- antitum
- fgfr
- harmful
- medicine
- intermitting
- Prior art date
Links
- 108091008794 FGF receptors Proteins 0.000 title 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013149963 | 2013-07-18 | ||
| PCT/JP2014/069086 WO2015008839A1 (ja) | 2013-07-18 | 2014-07-17 | Ｆｇｆｒ阻害剤の間歇投与用抗腫瘍剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3023100T3 true DK3023100T3 (da) | 2019-05-27 |
Family
ID=52346281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14826652.1T DK3023100T3 (da) | 2013-07-18 | 2014-07-17 | Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20160193210A1 (da) |
| EP (1) | EP3023100B1 (da) |
| JP (1) | JP6084291B2 (da) |
| KR (1) | KR101974254B1 (da) |
| AU (1) | AU2014291161B2 (da) |
| DK (1) | DK3023100T3 (da) |
| ES (1) | ES2724929T3 (da) |
| HU (1) | HUE044273T2 (da) |
| PL (1) | PL3023100T3 (da) |
| PT (1) | PT3023100T (da) |
| RU (1) | RU2664118C2 (da) |
| TR (1) | TR201907147T4 (da) |
| TW (1) | TWI574691B (da) |
| WO (1) | WO2015008839A1 (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3023100T3 (da) | 2013-07-18 | 2019-05-27 | Taiho Pharmaceutical Co Ltd | Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer |
| JP6084292B2 (ja) | 2013-07-18 | 2017-02-22 | 大鵬薬品工業株式会社 | Ｆｇｆｒ阻害剤耐性癌の治療薬 |
| CN105837575B (zh) * | 2015-01-13 | 2019-01-15 | 四川大学 | 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途 |
| US10434103B2 (en) * | 2015-03-31 | 2019-10-08 | Taiho Pharmaceutical Co., Ltd. | Crystal of 3,5-disubstituted benzene alkynyl compound |
| KR20250007056A (ko) | 2016-03-04 | 2025-01-13 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| CN107698593A (zh) * | 2016-08-09 | 2018-02-16 | 南京天印健华医药科技有限公司 | 作为fgfr抑制剂的杂环化合物 |
| CN107840842A (zh) | 2016-09-19 | 2018-03-27 | 北京天诚医药科技有限公司 | 炔代杂环化合物、其制备方法及其在医药学上的应用 |
| US11833151B2 (en) | 2018-03-19 | 2023-12-05 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
| TW202027749A (zh) * | 2018-10-12 | 2020-08-01 | 日商富士軟片股份有限公司 | 急性骨髓性白血病用抗腫瘤劑 |
| JP7161546B2 (ja) | 2018-11-09 | 2022-10-26 | 大鵬薬品工業株式会社 | ジメトキシベンゼン化合物の類縁物質、該化合物の分析方法及び標準品 |
| AU2018448845B2 (en) * | 2018-11-09 | 2022-03-24 | Taiho Pharmaceutical Co., Ltd. | Method for producing dimethoxybenzene compound |
| US20220023300A1 (en) * | 2018-11-26 | 2022-01-27 | Taiho Pharmaceutical Co., Ltd. | Therapeutic and prophylactic method for tumor treatable with endocrine therapy by combined use of fibroblast growth factor receptor inhibitor with endocrine therapy |
| WO2020170355A1 (ja) * | 2019-02-20 | 2020-08-27 | 大鵬薬品工業株式会社 | Ｆｇｆｒ１変異腫瘍の治療方法 |
| TW202200146A (zh) * | 2020-04-10 | 2022-01-01 | 日商大鵬藥品工業股份有限公司 | 使用有3,5-二取代苯炔基化合物與mek抑制劑之癌症治療法 |
| EP4161657A1 (en) * | 2020-06-05 | 2023-04-12 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| CN116057045B (zh) | 2020-06-05 | 2026-06-09 | 金耐特生物制药公司 | 成纤维细胞生长因子受体激酶抑制剂 |
| TWI797711B (zh) * | 2020-08-13 | 2023-04-01 | 大陸商上海和譽生物醫藥科技有限公司 | 一種fgfr及其突變抑制劑，其製備方法和應用 |
| CN114805359B (zh) * | 2021-01-28 | 2023-10-27 | 药雅科技(上海)有限公司 | 炔代杂环化合物fgfr抑制剂的制备方法和用途 |
| CN115028634B (zh) * | 2021-03-08 | 2023-11-28 | 药雅科技(上海)有限公司 | 一种炔代吡嗪并杂环类fgfr抑制剂及其制备方法和用途 |
| CN115785103A (zh) * | 2022-12-28 | 2023-03-14 | 北京康立生医药技术开发有限公司 | 一种治疗胆管癌药物福巴替尼的合成方法 |
| CN120172981B (zh) * | 2025-05-20 | 2025-07-25 | 南京工业大学 | 一类以fgfr2为靶点的小分子降解剂及其药物组合物和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005007083A2 (en) | 2003-06-18 | 2005-01-27 | Smithkline Beecham Corporation | Chemical compounds |
| JP2007509939A (ja) | 2003-10-27 | 2007-04-19 | ジェネラブズ テクノロジーズ インコーポレーティッド | ウイルス感染を治療するためのヌクレオシド化合物 |
| PE20070543A1 (es) * | 2005-10-06 | 2007-06-14 | Schering Corp | Pirazolopirimidinas como inhibidores de protein quinasas |
| DE602006021645D1 (de) | 2005-11-15 | 2011-06-09 | Array Biopharma Inc | Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten |
| EP1981890A2 (en) * | 2006-01-25 | 2008-10-22 | OSI Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
| WO2007095223A2 (en) | 2006-02-14 | 2007-08-23 | Vertex Pharmaceuticals Incorporated | Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases |
| US20100273776A1 (en) | 2006-03-29 | 2010-10-28 | FOLDRx PHARMACEUTICALS, INC | Inhibition of alpha-synuclein toxicity |
| EP1939197A1 (en) | 2006-12-22 | 2008-07-02 | Schwarz Pharma Ag | 8-ethinylxanthine derivatives as selective A2A receptor antagonists |
| EP2139487B1 (en) * | 2007-03-28 | 2015-11-11 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| CA2728063A1 (en) | 2008-06-19 | 2009-12-23 | Astrazeneca Ab | Pyrazole compounds 436 |
| GB0819105D0 (en) * | 2008-10-17 | 2008-11-26 | Chroma Therapeutics Ltd | Pyrrolo-pyrimidine compounds |
| ES2458872T3 (es) * | 2009-04-30 | 2014-05-07 | Novartis Ag | Derivados de imidazol y su uso como moduladores de quinasas dependientes de ciclina |
| KR101483215B1 (ko) * | 2010-01-29 | 2015-01-16 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| US9140689B2 (en) | 2010-03-14 | 2015-09-22 | Translational Genomics Research Institute | Methods of determining susceptibility of tumors to tyrosine kinase inhibitors |
| DE102011015188A1 (de) | 2010-03-29 | 2011-09-29 | Herbert Kannegiesser Gmbh | Verfahren zur Nassbehandlung, insbesondere zum Reinigen, von Gegenständen |
| MX380504B (es) * | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| CN103459400B (zh) | 2011-04-06 | 2016-05-18 | 大鹏药品工业株式会社 | 咪唑并噁嗪化合物或其盐 |
| UY34484A (es) | 2011-12-15 | 2013-07-31 | Bayer Ip Gmbh | Benzotienilo-pirrolotriazinas disustituidas y sus usos |
| AU2013210403B2 (en) | 2012-01-19 | 2016-01-14 | Taiho Pharmaceutical Co., Ltd. | 3,5-disubstituted alkynylbenzene compound and salt thereof |
| CA2865021C (en) | 2012-02-23 | 2020-06-30 | Bayer Intellectual Property Gmbh | Substituted benzothienyl-pyrrolotriazines and uses thereof |
| WO2014007217A1 (ja) | 2012-07-02 | 2014-01-09 | 大鵬薬品工業株式会社 | イミダゾオキサジン化合物による抗腫瘍効果増強剤 |
| EP2692740A1 (en) | 2012-07-30 | 2014-02-05 | Le Centre National De La Recherche Scientifique | Glycan compositions, processes for preparing the same and their uses as a drug |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| JP2016510751A (ja) | 2013-03-06 | 2016-04-11 | ジェネンテック， インコーポレイテッド | 抗がん剤耐性を治療及び予防する方法 |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| JP6289459B2 (ja) | 2013-06-20 | 2018-03-07 | 大鵬薬品工業株式会社 | ＰＨＬＤＡ１又はＰＩＫ３Ｃ２Ｂの発現に基づくＰＩ３Ｋ／ＡＫＴ／ｍＴＯＲ阻害剤の治療効果の予測方法 |
| JP6084292B2 (ja) | 2013-07-18 | 2017-02-22 | 大鵬薬品工業株式会社 | Ｆｇｆｒ阻害剤耐性癌の治療薬 |
| DK3023100T3 (da) | 2013-07-18 | 2019-05-27 | Taiho Pharmaceutical Co Ltd | Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer |
| WO2015163448A1 (ja) | 2014-04-25 | 2015-10-29 | 中外製薬株式会社 | ４環性化合物を高用量含有する製剤 |
| CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| CN105859721B (zh) | 2015-01-22 | 2018-04-17 | 浙江京新药业股份有限公司 | 一种伊布鲁替尼的制备方法 |
| CN107428779A (zh) | 2015-02-27 | 2017-12-01 | 大鹏药品工业株式会社 | 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法 |
| US10434103B2 (en) | 2015-03-31 | 2019-10-08 | Taiho Pharmaceutical Co., Ltd. | Crystal of 3,5-disubstituted benzene alkynyl compound |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| EA201890161A1 (ru) | 2015-06-29 | 2018-06-29 | Верастэм, Инк. | Терапевтические композиции, комбинации и способы применения |
| US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| KR20250007056A (ko) | 2016-03-04 | 2025-01-13 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
-
2014
- 2014-07-17 DK DK14826652.1T patent/DK3023100T3/da active
- 2014-07-17 TR TR2019/07147T patent/TR201907147T4/tr unknown
- 2014-07-17 PL PL14826652T patent/PL3023100T3/pl unknown
- 2014-07-17 EP EP14826652.1A patent/EP3023100B1/en active Active
- 2014-07-17 JP JP2015527336A patent/JP6084291B2/ja active Active
- 2014-07-17 TW TW103124539A patent/TWI574691B/zh active
- 2014-07-17 PT PT14826652T patent/PT3023100T/pt unknown
- 2014-07-17 AU AU2014291161A patent/AU2014291161B2/en active Active
- 2014-07-17 KR KR1020167003764A patent/KR101974254B1/ko active Active
- 2014-07-17 US US14/905,420 patent/US20160193210A1/en not_active Abandoned
- 2014-07-17 WO PCT/JP2014/069086 patent/WO2015008839A1/ja not_active Ceased
- 2014-07-17 HU HUE14826652 patent/HUE044273T2/hu unknown
- 2014-07-17 ES ES14826652T patent/ES2724929T3/es active Active
- 2014-07-17 RU RU2016105133A patent/RU2664118C2/ru active
-
2019
- 2019-02-13 US US16/274,573 patent/US10894048B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190183897A1 (en) | 2019-06-20 |
| RU2016105133A3 (da) | 2018-02-28 |
| KR101974254B1 (ko) | 2019-04-30 |
| EP3023100A4 (en) | 2017-01-04 |
| US20160193210A1 (en) | 2016-07-07 |
| KR20160032186A (ko) | 2016-03-23 |
| RU2664118C2 (ru) | 2018-08-15 |
| RU2016105133A (ru) | 2017-08-23 |
| EP3023100B1 (en) | 2019-03-13 |
| JPWO2015008839A1 (ja) | 2017-03-02 |
| PT3023100T (pt) | 2019-05-29 |
| EP3023100A1 (en) | 2016-05-25 |
| TR201907147T4 (tr) | 2019-06-21 |
| TW201536294A (zh) | 2015-10-01 |
| HUE044273T2 (hu) | 2019-10-28 |
| JP6084291B2 (ja) | 2017-02-22 |
| ES2724929T3 (es) | 2019-09-17 |
| AU2014291161A1 (en) | 2016-02-25 |
| WO2015008839A1 (ja) | 2015-01-22 |
| AU2014291161B2 (en) | 2018-04-26 |
| US10894048B2 (en) | 2021-01-19 |
| TWI574691B (zh) | 2017-03-21 |
| PL3023100T3 (pl) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2961388T3 (da) | Kombinationer af lægemidler | |
| HUE037587T2 (hu) | Önálló fecskendõcsatlakozás | |
| HRP20180684T1 (hr) | Kombinacija lijekova | |
| DK2968208T3 (da) | Behandling af kataplexi | |
| DK2968071T3 (da) | Enhed til oral levering af terapeutiske forbindelser | |
| DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
| HUE035943T2 (hu) | Automata fecskendõ | |
| DK3669913T3 (da) | Anordning til indgivelse af lægemidler | |
| DK3611262T3 (da) | Fremgangsmåder til sekvensering af immunrepertoire | |
| DK3062849T3 (da) | Medikamentadministrationsanordning | |
| EP2968894A4 (en) | MEDICAL CONNECTOR | |
| DK2964315T3 (da) | System til behandling af neuromotorisk dysfunktion | |
| LT3381444T (lt) | Švirkštas | |
| DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
| DK2970389T3 (da) | Farmaceutiske forbindelser | |
| EP4005604C0 (en) | ADMINISTRATION OF MEDICINES | |
| EP3016703C0 (en) | SAFETY SYRINGE | |
| DK3287133T3 (da) | Proton-bindende polymerer til oral indgivelse | |
| PT2953948T (pt) | Antagonistas de integrina fluorada | |
| DK3007726T3 (da) | Fremgangsmåder til behandling af en tauopati | |
| DK3363428T3 (da) | Perfusionsdoseringsform | |
| DK3024519T3 (da) | Destruktion af hypodermiske kanyler | |
| DK3065790T3 (da) | Fremgangsmåder til fjernelse af alpha-galactose | |
| DK3094322T3 (da) | Administration af tasimelteon i fastende tilstand | |
| EP2945942A4 (en) | Voriconazole IMMUNOASSAY |